Association study of TP53 polymorphisms with lung cancer in a Korean population

Journal of Human Genetics

Volumn 53, Issue 6, 2008, Pages 508-514

  Jung, Hae Yun ^a   Whang, Young Mi ^a   Sung, Jae Sook ^a   Shin, Hyoung Doo ^a,b   Park, Byung Lae ^a,b   Kim, Jun Suk ^a   Shin, Sang Won ^a   Seo, Hee Yun ^a   Seo, Jae Hong ^a   Kim, Yeul Hong ^a  

^a Korea University College of Medicine   (South Korea)

^b SNP Genetics Inc   (South Korea)

Author keywords

Haplotypes; Korean population; Lung cancer; Single nucleotide polymorphisms; Tumor protein p53 (TP53)

Indexed keywords

ARGININE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA POLYMORPHISM; DNA SEQUENCE; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HUMAN; KOREA; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ALLELES; BASE SEQUENCE; CASE-CONTROL STUDIES; DNA, NEOPLASM; FEMALE; GENES, P53; HAPLOTYPES; HUMANS; KOREA; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 44449173940     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10038-008-0278-y     Document Type: Article

References (27)

1. de las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, Massuti B, Queralt C, Botia M, Garcia-Gomez R, others (2006) Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine- treated non-small-cell lung cancer patients. Ann Oncol 17(4):668-675
2. Fuster JJ, Sanz-Gonzalez SM, Moll UM, Andres V (2007) Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol Med 13(5):192-199
3. Hainaut P, Hollstein M (2000) p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77:81-137
4. Hazelton WD, Clements MS, Moolgavkar SH (2005) Multistage carcinogenesis and lung cancer mortality in three cohorts. Cancer Epidemiol Biomarkers Prev 14(5):1171-1181
5. Hedrick PW (1987) Gametic disequilibrium measures: proceed with caution. Genetics 117(2):331-341
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253(5015):49-53
7. Jin X, Wu X, Roth JA, Amos CI, King TM, Branch C, Honn SE, Spitz MR (1995) Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 16(9):2205-2008
8. Kastan MB, Canman CE, Leonard CJ (1995) P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 14(1):3-15
9. Khadang B, Fattahi MJ, Talei A, Dehaghani AS, Ghaderi A (2007) Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet 173(1):38-42
10. Matakidou A, Eisen T, Houlston RS (2003) TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 18(4):377-385
11. Mechanic LE, Bowman ED, Welsh JA, Khan MA, Hagiwara N, Enewold L, Shields PG, Burdette L, Chanock S, Harris CC (2007) Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol Biomarkers Prev 16(2):214-222
12. Nadji SA, Mahmoodi M, Ziaee AA, Naghshvar F, Torabizadeh J, Yahyapour Y, Nategh R, Mokhtari-Azad T (2007) An increased lung cancer risk associated with codon 72 polymorphism in the TP53 gene and human papillomavirus infection in Mazandaran province, Iran. Lung Cancer 56(2):145-151
13. Nyholt DR (2004) A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 74(4):765-769
14. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26(15):2157-2165
15. Pierce LM, Sivaraman L, Chang W, Lum A, Donlon T, Seifried A, Wilkens LR, Lau AF, Le Marchand L (2000) Relationships of TP53 codon 72 and HRAS1 polymorphisms with lung cancer risk in an ethnically diverse population. Cancer Epidemiol Biomarkers Prev 9(11):1199-1204
16. Popanda O, Edler L, Waas P, Schattenberg T, Butkiewicz D, Muley T, Dienemann H, Risch A, Bartsch H, Schmezer P (2007) Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer 55(1):25-34
17. Rajaraman P, Wang SS, Rothman N, Brown MM, Black PM, Fine HA, Loeffler JS, Selker RG, Shapiro WR, Chanock SJ, others (2007) Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev 16(8):1655-1661
18. Sanchez-Cespedes M (2003) Dissecting the genetic alterations involved in lung carcinogenesis. Lung Cancer 40(2):111-121
19. Shin HR, Won JY, Jung KW, Kong KW, Yim SH, Lee JK, Noh HI, Lee JK, Pisani P, Park JG (2005) Nationwide cancer incidence in Korea, 1999-2001; first result using the national cancer incidence database. Cancer Res Treatment 37(6):325-331
20. Soussi T (2007) p53 alterations in human cancer: more questions than answers. Oncogene 26(15):2145-2156
21. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, Tornielli S, Sard L, Huebner K, Pierotti MA, others (1998) Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 58(22):5032-5037
22. Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68(4):978-989
23. Toloza EM, Morse MA, Lyerly HK (2006) Gene therapy for lung cancer. J Cell Biochem 99(1):1-22
24. Wistuba II, Gazdar AF, Minna JD (2001) Molecular genetics of small cell lung carcinoma. Semin Oncol 28(2 Suppl 4):3-13
25. Yokomizo A, Tindall DJ, Drabkin H, Gemmill R, Franklin W, Yang P, Sugio K, Smith DI, Liu W (1998) PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 17(4):475-479
26. Zambetti GP (2007) The p53 mutation "gradient effect" and its clinical implications. J Cell Physiol 213(2):370-373
27. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, Wang Y, Lin D (2006) Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 27(1):110-117